Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G CHRISTENSEN

Showing results (491-500 of 608) with videos related to

Pageof 61
Sort By:
Molecular Cancer Therapeutics|December 3, 2011
Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancerHyun-Jin Nam, Keith A Ching, Julie Kan, et al.
Carcinogenesis|July 30, 1999
Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in miceJ G Christensen, E H Romach, L N Healy, et al.
British Journal of Pharmacology|July 2, 2013
SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardiumL R Moltzau, J M Aronsen, S Meier, et al.
Journal of Medicinal Chemistry|November 1, 1970
Inhibition of adrenal phenethanolamine N-methyltransferase by substituted benzimidazolesL R Mandel, C C Porter, F A Kuehl, et al.
The Journal of the American Academy of Orthopaedic Surgeons|December 10, 2025
Minimum 48-month Clinical and Radiographic Outcomes of Anatomic Total Shoulder Arthroplasty With a Partially Cemented All-polyethylene Fluted Central Peg Glenoid ComponentRose G Christensen, Branum G Griswold, Benjamin W Sears, et al.
Plos One|June 30, 2012
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationNathan V Lee, Maruja E Lira, Adam Pavlicek, et al.
Oncogene|February 2, 2010
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorD Ercan, K Zejnullahu, K Yonesaka, et al.
Acta Oncologica (Stockholm, Sweden)|January 31, 2019
MyHealth: specialist nurse-led follow-up in breast cancer. A randomized controlled trial - development and feasibilityLena Saltbæk, Randi V Karlsen, Pernille E Bidstrup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET InhibitionThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Molecular Cancer Therapeutics|July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinibOndrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Pageof 61

Showing results (491-500 of 608) with videos related to

Sort By:
Pageof 61
Molecular Cancer Therapeutics|December 3, 2011
Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancerHyun-Jin Nam, Keith A Ching, Julie Kan, et al.
Carcinogenesis|July 30, 1999
Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in miceJ G Christensen, E H Romach, L N Healy, et al.
British Journal of Pharmacology|July 2, 2013
SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardiumL R Moltzau, J M Aronsen, S Meier, et al.
Journal of Medicinal Chemistry|November 1, 1970
Inhibition of adrenal phenethanolamine N-methyltransferase by substituted benzimidazolesL R Mandel, C C Porter, F A Kuehl, et al.
The Journal of the American Academy of Orthopaedic Surgeons|December 10, 2025
Minimum 48-month Clinical and Radiographic Outcomes of Anatomic Total Shoulder Arthroplasty With a Partially Cemented All-polyethylene Fluted Central Peg Glenoid ComponentRose G Christensen, Branum G Griswold, Benjamin W Sears, et al.
Plos One|June 30, 2012
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationNathan V Lee, Maruja E Lira, Adam Pavlicek, et al.
Oncogene|February 2, 2010
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorD Ercan, K Zejnullahu, K Yonesaka, et al.
Acta Oncologica (Stockholm, Sweden)|January 31, 2019
MyHealth: specialist nurse-led follow-up in breast cancer. A randomized controlled trial - development and feasibilityLena Saltbæk, Randi V Karlsen, Pernille E Bidstrup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET InhibitionThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Molecular Cancer Therapeutics|July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinibOndrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Pageof 61